In April 2025, the U.S. Food and Drug Administration (FDA) — the federal agency responsible for regulating food, drugs, medical products, and other health-related items — announced a significant advancement in regulatory science by replacing the requirement for animal testing for monoclonal antibodies and other drugs with more modern and effective methods.
The initiative aims to make the development of new drugs safer and more efficient by promoting alternatives such as AI-based computational toxicity models and lab tests using human cells. Additionally, safety data from drugs already evaluated in other countries may now be considered, reducing the need for additional studies.
According to the FDA, this change is expected to accelerate the approval of new treatments, reduce research and development costs, and contribute to ending large-scale animal testing.
More details can be found in the FDA’s official announcement.
